Suppression of MiR130a-3p Using CRISPR/Cas9 Induces Proliferation and  Migration of Non-Small Cell Lung Cancer Cell Line

Abdollah, Nur Ainina; Safiai, Nabil Izzatie Mohamad; Ahmad, Muhammad Khairi; Das, Kumitaa Theva; Razak, Siti Razila Abdul

doi:10.18585/inabj.v13i4.1670

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the initial benefits observed with TKI therapy, a majority of NSCLC patients with active EGFR mutations develop resistance during treatment. (1) Since there has been a significant breakthrough in the management of NSCLC with a specific genetic alteration (10)(11)(12), there was substantial condition improvement in patients whose cancer progressed after first-generation TKI treatment and who developed tumors with EGFR Exon 20 T790M mutation. (13) The T790M mutation in NSCLC play role in reducing adenosine triphosphate (ATP)-competitivekinase-inhibitor, so that the mutation can prevent the effect of inhibitor, thus EGFR-mediated signalling will not be defected.…”

Section: Methods Introductionmentioning

confidence: 99%

Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M

Zam,

Iskandar,

Tabri

et al. 2023

Indones Biomed J

View full text Add to dashboard Cite

BACKGROUND: Emergence of drug resistance due to epidermal growth factor receptor (EGFR) Exon 20 T790M poses a challenge in the effective management of non-small cell lung carcinoma (NSCLC). Significant breakthrough in the management of NSCLC with a specific genetic alteration causes substantial condition improvement in patients whose cancer progressed after first-generation tyrosine kinase inhibitor treatment and who developed tumors with EGFR Exon 20 T790M mutation. The present study analyzed a cohort of NSCLC patients and investigated the incidence of the EGFR Exon 20 T790M status with Osimertinib therapy, along with its impact on survival rates.METHODS: This was a retrospective cohort study on 22 NSCLC subjects who were genetically examined for EGFR status from plasmic cell free total nucleic acid. Subjects with EGFR Exon 20 T790M mutation were treated with/without Osimertinib. Demographic and clinical data were descriptively summarized, and the differences of each variable and correlation between survival rate and EGFR Exon 20 T790M were analyzed.RESULTS: Subjects with (n=13) and without (n=9) EGFR Exon 20 T790M had survival rates of 10.77±2.45 and 4.78±1.48, respectively (p=0.000). Based on 1-year survival status of subjects with EGFR Exon 20 T790M, there were 3 Osimertinib-treated survivors and 2 Osimertinib-treated non-survivors. Eight subjects with EGFR Exon 20 T790M and without Osimertinib treatment did not survive (p=0.001).CONCLUSION: Since the treatment of Osimertinib demonstrated a noteworthy survival rate among NSCLC subjects with EGFR Exon 20 T790M, thus Osimertinib could be suggested as a potential targeted therapy for NSCLC subjects with EGFR Exon 20 T790M.KEYWORDS: non-small cell lung carcinoma, EGFR, Exon 20, T790M, osimertinib

show abstract

Section: Methods Introductionmentioning

confidence: 99%

Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M

Zam,

Iskandar,

Tabri

et al. 2023

Indones Biomed J

View full text Add to dashboard Cite

show abstract

“…The Indonesian Biomedical Journal, Vol 15,. No.2, April 2023, p.106-93 Print ISSN: 2085-3297, Online ISSN: 2355-9179…”

mentioning

confidence: 99%

GSTM1 Deletion Compensated in mRNA Expression and 4T1 Viability After Editing Using CRISPR/Cas9 Single and Double gRNA

Arsita

Nugrahaningsih

Sadewa³

2023

Indones Biomed J

View full text Add to dashboard Cite

BACKGROUND: Glutathione S-transferase Mu-1 (GSTM1) is known to undergo polymorphism and plays role in drug metabolism including Paclitaxel (PTX), the first-line chemotherapy for breast cancer. However, the effect of GSTM1 polymorphism against chemotherapy in breast cancer is limited and unexplored. This study was conducted to explore the effects of single and double guide (gRNA) on the GSTM1 knocked out (KO) and its effect on the response of PTX in the 4T1 cell line.METHODS: The preparatory stage was done by culturing and electroporating 4T1 cells using Ribonucleoprotein of clustered regularly interspaced short palindromic repeats (CRISPR)/Caspase 9 (Cas9). KO validation was examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR), Sanger sequencing, and ICE analysis. The 4T1 viability was examined by MTT Assay.RESULTS: The number of base pairs of GSTM1 after being engineered by single or double gRNA was 86 bases. The DNA quantity of GSTM1 engineered by gRNA was more than using double gRNAs. The mRNA expression of GSTM1 engineered by single gRNA was lower than using double gRNAs. IC50 values of PTX between wildtype and KO were not significantly different, in the range of 30 µM.CONCLUSION: The base-pair length of GSTM1 exon 4 that is knocked out with single and double gRNA have the same number of base pairs. The quantity of GSTM1 DNA and mRNA expression are contrary between single gRNA and double gRNA, and IC50 PTX values in the 4T1 cell line of the control group with single or double gRNA knocked out do not differ markedly. PTX efficiency as chemotherapy is not disturbed in the GSTM1 deletion genetic profile.KEYWORDS: GSTM1, gRNA, Paclitaxel, CRISPR, breast cancer

show abstract

MicroRNAs and colorectal cancer: clinical potential and regulatory networks

Osei,

Adu-Amankwaah,

Koomson

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

Suppression of MiR130a-3p Using CRISPR/Cas9 Induces Proliferation and Migration of Non-Small Cell Lung Cancer Cell Line

Cited by 3 publications

References 41 publications

Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M

Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M

GSTM1 Deletion Compensated in mRNA Expression and 4T1 Viability After Editing Using CRISPR/Cas9 Single and Double gRNA

MicroRNAs and colorectal cancer: clinical potential and regulatory networks

Contact Info

Product

Resources

About